Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands

ConclusionIn the Netherlands, baloxavir is a cost-effective treatment option for seasonal influenza, with a base-case ICER of €8,300 per QALY for the population aged 60 years and over and patients at high risk of influenza-related complications. For a large part, this ICER is driven by the reduction of the illness duration of influenza and productivity gains in the working population.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research